Therapeutic uses of a c-raf inhibitor
作者： Giordano Caponigro , Anna Helena Mais , Vesselina Cooke , Heidi Nauwelaerts
DOI:
关键词: c-Raf 、 Humanized antibody 、 Cancer research 、 Protein kinase A 、 Programmed death 1 、 Chemistry 、 Antibody molecule 、 MAPK/ERK pathway 、 Solid tumor 、 Proliferative disease
摘要: The present invention relates to the use of a c-Raf inhibitor for in treatment proliferative disease, particularly solid tumor that harbors Mitogen-activated protein kinase (MAPK). also pharmaceutical combination which comprises (a) at least one antibody molecule (e.g., humanized molecules) binds Programmed Death 1 (PD-1), and (b) or pharmaceutically acceptable salt thereof. such simultaneous, separate sequential administration (MAPK) alteration commercial package comprising combination.
lens.org参考文章(11)
G. M. Grass, J. R. Robinson, Sustained- and controlled-release drug delivery systems Drugs and the pharmaceutical sciences. ,vol. 40, pp. 635- 671 ,(1978)
Walter A. Blattler, Catherine Anne Sabatos-Peyton, Arlene Helen Sharpe, Jennifer Marie Mataraza, Gordon James Freeman, Gerhard Johann Frey, Hwai Wen Chang, Antibody molecules to pd-1 and uses thereof ,(2015)
Elvin A. Kabat, Sequences of proteins of immunological interest National Institutes of Health. ,(1991)
Savithri Ramurthy, Benjamin R. Taft, Naeem Yusuff, Robert John Aversa, Gisele A. Nishiguchi, Alice C. Rico, Yue Pan, Yan Lou, Alan DiPesa, Sharadha Subramanian, Lifeng Wan, Lina Quattrocchio Setti, Cheng Hu, Michael Patrick Dillon, Valery Rostislavovich Polyakov, Matthew T. Burger, Huw Roland Tanner, Aaron Smith, Paul Andrew Barsanti, Biaryl amide compounds as kinase inhibitors ,(2014)
Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J. Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S. Ho, Martin L. Miller, Natasha Rekhtman, Andre L. Moreira, Fawzia Ibrahim, Cameron Bruggeman, Billel Gasmi, Roberta Zappasodi, Yuka Maeda, Chris Sander, Edward B. Garon, Taha Merghoub, Jedd D. Wolchok, Ton N. Schumacher, Timothy A. Chan, Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer Science. ,vol. 348, pp. 124- 128 ,(2015) , 10.1126/SCIENCE.AAA1348
Piro Lito, Anna Saborowski, Jingyin Yue, Martha Solomon, Eric Joseph, Sunyana Gadal, Michael Saborowski, Edward Kastenhuber, Christof Fellmann, Kazuhiro Ohara, Kenji Morikami, Takaaki Miura, Christine Lukacs, Nobuya Ishii, Scott Lowe, Neal Rosen, Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors Cancer Cell. ,vol. 25, pp. 697- 710 ,(2014) , 10.1016/J.CCR.2014.03.011
Alasdair J. Leslie, Meryn Griffiths, Colin Stubberfield, Robert Griffin, Alistair J. Henry, Andreas Jansson, John E. Ladbury, Shinji Ikemizu, Mark D. Carr, Simon J. Davis, Xiaoxiao Cheng, Vaclav Veverka, Anand Radhakrishnan, Lorna C. Waters, Frederick W. Muskett, Sara H. Morgan, Jiandong Huo, Chao Yu, Edward J. Evans, Structure and Interactions of the Human Programmed Cell Death 1 Receptor Journal of Biological Chemistry. ,vol. 288, pp. 11771- 11785 ,(2013) , 10.1074/JBC.M112.448126
Rafael B. Blasco, Sarah Francoz, David Santamaría, Marta Cañamero, Pierre Dubus, Jean Charron, Manuela Baccarini, Mariano Barbacid, c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma Cancer Cell. ,vol. 19, pp. 652- 663 ,(2011) , 10.1016/J.CCR.2011.04.002
Michael Fara, Camelia S. Sima, Vincent A. Miller, Mark G. Kris, Marc Ladanyi, Gregory J. Riely, Paul K. Paik, Maria E. Arcila, Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations Journal of Clinical Oncology. ,vol. 29, pp. 2046- 2051 ,(2011) , 10.1200/JCO.2010.33.1280
Melissa Junttila, Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors ,(2015)